Search

Objectives: To investigate the effect of enalapril, losartan, and surgical coronary revascularisation on endothelial function, and the role of the angiotensin converting enzyme (ACE) insertion (I)/deletion (D) polymorphism., Design: Randomised, controlled, blinded end point study., Setting: University tertiary referral cardiac centre., Patients and Interventions: 49 men awaiting coronary artery bypass grafting (CABG) were randomly assigned to treatment with losartan, enalapril, or control for two months before and three months after surgery., Main Outcome Measures: Endothelial function was blindly analysed by brachial artery flow mediated dilatation (FMD) and ACE I/D genotype was determined., Results: FMD was impaired at baseline (1.0-1.7%) and after five months had improved to 5.2% with enalapril (p = 0.015), 5.0% with losartan (p = 0.0004), and 3.0% with CABG alone (p = 0.05). Patients with the II genotype had lower baseline FMD than those with DI or DD (0.1% v 1.7%, p = 0.038) and after enalapril or losartan treatment had greater improvement in FMD (mean (SEM) 7.1 (1.1)%) than patients with DI (3.1 (1.3)%, p = 0.024) or DD genotype (3.1 (1.1)%, p = 0.02)., Conclusions: Enalapril and losartan, with surgical coronary revascularisation, significantly improve systemic endothelial function. Revascularisation alone produces a quantitatively smaller, but still significant, improvement. The ACE genotype significantly modulates this response. Patients with the II genotype have a more pronounced impairment in endothelial function at baseline and a greater improvement in response to treatment with these agents.

Objective: To assess the degree and sources of current diagnostic inaccuracy of serial conventional cardiac markers and ECGs compared with the new diagnostic criteria for myocardial infarction, with specific reference to physician specialty and the prognostic value of troponin T., Design: Prospective, blinded observational study., Setting: University hospital., Patients and Interventions: All suspected cardiac chest pain admissions for six months, with additional blinded measurement of CK-MB mass and troponin T. World Health Organization and new criteria myocardial infarction diagnoses were made by an expert panel., Main Outcome Measures: Diagnostic adjustment by expert panel; completeness of serial measurements; six months prognosis., Results: A complete set of serial cardiac markers was not taken in 38.7% of patients, this being twice as likely when managed by non-cardiologists than by cardiologists (p < 0.0001). The WHO myocardial infarction diagnosis was adjusted by the expert panel in 4% of cases, this being 90% more likely in patients admitted under non-cardiologists (p = 0.026). The new criteria for myocardial infarction identified an additional 27.3% of infarcts, with a diagnostic alteration in 12.0% of the cohort; 45.2% of these cases had a potentially preventable cause for diagnostic adjustment. Only troponin T (p = 0.0004), ST depression (p = 0.003), and heart failure (p = 0.016) were independently predictive of prognosis., Conclusions: Chest pain patients appear less likely to be fully and accurately assessed by non-cardiologists than by cardiologists. The new criteria for myocardial infarction identify approximately 25% of additional patients as MI, with potential additional advantages related to simplicity of diagnostic protocols. Troponin T was the most potent predictor of six month prognosis in an unselected cohort of chest pain admissions.